-
Duality Biotherapeutics’ BDCA2 ADC DB-2304 Phase I Trial Registered on ClinicalTrials.gov
•
Duality Biotherapeutics, Inc., a biopharmaceutical company specializing in the development of innovative therapies, has registered a Phase I clinical trial for its drug candidate DB-2304 on ClinicalTrials.gov as of October 3, 2024. The trial is designed to enroll 70 healthy volunteers and is anticipated to conclude in the first half…
-
Duality Biotherapeutics Initiates Global Clinical Trial for DB-1419 in Advanced Solid Tumors
•
Duality Biotherapeutics, Inc., a biopharmaceutical company based in China, has reached a significant milestone with the dosing of the first patient in its Phase I/IIa clinical study for the in-house developed antibody drug conjugate (ADC) DB-1419. The study is aimed at evaluating the safety and efficacy of DB-1419 in patients…
-
Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials
•
HONG KONG—Duality Biotherapeutics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is planning an initial public offering (IPO) on the Hong Kong Stock Exchange. While the unit price and further details remain under wraps, the company’s ambitions are clear, with a robust pipeline of 12 innovative ADCs…
